Keywords: USA, FDA advisory, Bristol-Myers Squibb, AstraZeneca, Dapagliflozin, Type 2 diabetes
US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues
Article | 20 July 2011
The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted to not recommend approval of Anglo-Swedish ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
